Posts by: Steve Bryson PhD

Steve Bryson PhD

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.

March 29, 2021March 29, 2021

Lassen, Cedars Sinai Partner to Advance Antibody Therapies for IPF

News

Lassen Therapeutics and researchers at Cedars Sinai Medical Center in California will together investigate the role of the immune signaling protein interleukin-11 (IL-11) in idiopathic pulmonary fibrosis (IPF), and its ... Read more

February 24, 2021February 24, 2021

PDGFA Found to Stimulate Lung Tissue Repair in Aged IPF Mice

News

Pretreatment with retinoic acid was found to stimulate the repair of damaged alveoli — the tiny air sacs in the lungs — in a mouse model of idiopathic pulmonary fibrosis ... Read more

February 23, 2021February 23, 2021

DNA Sensor Protein STING May Protect Against Fibrosis, Mouse Study Shows

News

A DNA sensor protein called STING was found to play an unexpected protective role in fibrosis development by regulating inflammatory immune responses in an induced idiopathic pulmonary fibrosis (IPF) mouse ... Read more

November 11, 2020November 11, 2020

Esbriet or Ofev Reduce Inflammatory and Oxidative Stress Markers in IPF, Small Study Shows

News

Esbriet (pirfenidone) or Ofev (nintedanib) treatment in adults with idiopathic pulmonary fibrosis (IPF) led to changes in blood markers reflecting reduced systemic inflammation and oxidative stress after 24 weeks of ... Read more

November 6, 2020November 6, 2020

Anticoagulant DOACs Better Than Warfarin in IPF, Analysis Finds

News

Use of the well-known anticoagulant therapy warfarin in people with idiopathic pulmonary fibrosis (IPF) is associated with reduced transplant-free survival, but direct oral anticoagulants (DOACs) are not, a study found. ... Read more

November 4, 2020November 4, 2020

Ofev, Esbriet Use Seen to Lengthen Life for IPF Patients With ‘Mild’ Disease

News

A real-world analysis found that idiopathic pulmonary fibrosis (IPF) patients with preserved lung function benefitted from treatment with Ofev (nintedanib) and Esbriet (pirfenidone) over three years. Despite untreated patients entering this ... Read more

September 9, 2020September 9, 2020

Inhaled Nintedanib May Reduce Side Effects of Oral Formulation, Rat Study Shows

News

An inhaled formulation of nintedanib — the active ingredient in Ofev — demonstrated enhanced antifibrotic effects after short-duration doses compared to oral formulations given at a higher dose in a ... Read more

September 8, 2020September 10, 2020

Ofev Effective in IPF Patients With Poor Lung Function, Real-world Study Finds

News

Ofev (nintedanib) is safe and effective for adults with idiopathic pulmonary fibrosis (IPF) with poorer lung function, a small real-world analysis has found. Age and lung function predicted the therapy’s ... Read more

September 2, 2020September 2, 2020

Specific Gene Mutation Linked to PF and Emphysema in Japanese Patients, Study Suggests

News

Japanese people diagnosed with both pulmonary fibrosis (PF) and emphysema appear to carry a single genetic mutation that contributes to the development of both conditions, a study reports. This mutation ... Read more

August 21, 2020August 21, 2020

Adelmidrol Effectively Treated Pulmonary Fibrosis in Mice, Study Finds

News

Adelmidrol therapy reduced markers for inflammation and oxidative stress, as well as tissue damage and collagen deposits, in the lungs of mice with pulmonary fibrosis (PF), a study has found. The ... Read more